Zimmer Biomet (ZBH.SW) experienced a significant pre-market volume spike, trading at CHF67.50 on the SIX exchange, marking a notable decline. The stock plummeted 4.26% from its previous close, reaching a new year low. Despite Meyka AI assigning a B+ (BUY) grade, its predictive model forecasts a potential 16.00% downside over the next 12 months, projecting a target price of CHF56.70. This divergence between the rating and forecast highlights prevailing market uncertainty. Traders are advised to closely monitor the crucial support level at CHF67.50 and the 50-day moving average at CHF78.58 for potential future movements.
Get AI-powered deep analysis for every story with a paid subscription
Upgrade for Analysis